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Frontiers in Immunology

Since ﬁrst reported in 2019, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is rapidly acquiring mutations, particularly in the spike protein, that
can modulate pathogenicity, transmission and antibody evasion leading to
successive waves of COVID19 infections despite an unprecedented mass
vaccination necessitating continuous adaptation of therapeutics. Small animal
models can facilitate understanding host-pathogen interactions, target selection
for therapeutic drugs, and vaccine development, but availability and cost of studies
in BSL3 facilities hinder progress. To generate a BSL2-compatible in vivo system
that speciﬁcally recapitulates spike protein mediated disease we used replication
competent, GFP tagged, recombinant Vesicular Stomatitis Virus where the VSV
glycoprotein was replaced by the SARS-CoV-2 spike protein (rVSV-SARS2-S). We
show that infection requires hACE2 and challenge of neonatal but not adult, K18hACE2 transgenic mice (hACE2tg) leads to productive infection of the lungs and
brains. Although disease progression was faster in SARS-CoV-2 infected mice,
infection with both viruses resulted in neuronal infection and encephalitis with
increased expression of Interferon-stimulated Irf7, Bst2, Iﬁ294, as well as CxCL10,
CCL5, CLC2, and LILRB4, and both models were uniformly lethal. Further,
prophylactic treatment targeting the Spike protein (Receptor Binding Domain)
with antibodies resulted in similar levels of protection from lethal infection against
rVSV-SARS2-S and SARS-CoV-2 viruses. Strikingly, challenge of neonatal hACE2tg
mice with SARS-CoV-2 Variants of Concern (SARS-CoV-2-a, -b, ϒ, or D) or the
corresponding rVSV-SARS2-S viruses (rVSV-SARS2-Spike-a, rVSV-SARS2-Spike-b,
rVSV-SARS2-Spike-ϒ or rVSV-SARS2-Spike-D) resulted in increased lethality,
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suggesting that the Spike protein plays a key role in determining the virulence of
each variant. Thus, we propose that rVSV-SARS2-S virus can be used to understand
the effect of changes to SARS-CoV-2 spike protein on infection and to evaluate
existing or experimental therapeutics targeting spike protein of current or future
VOC of SARS-CoV-2 under BSL-2 conditions.
KEYWORDS

SARS-CoV-2, spike protein, neurotropism, BSL-2 mouse model, pseudotyped virus,
ACE2 transgenic mice, VSV (vesicular stomatitis virus), COVID-19

Introduction

understanding correlates of efﬁcacy and to screen and test
antibodies targeting the SARS-CoV-2 spike protein (11, 12).
Several animal models have been developed to assess SARSCoV-2 therapeutics, including in non-human primates, hamsters,
ferrets, dogs and mice, but few are uniformly symptomatic, and
none can be performed outside of a BSL3 facility (13–17).
Availability of a model that can be used in BSL2 labs would
facilitate rapid product development and testing as cost and space
availability severely limit studies that require BSL3 conditions. In a
previous study we reported that administration of replication
competent recombinant Vesicular Stomatitis Virus (VSV) where
the native glycoprotein (VSV-G) is replaced by Ebola virus
glycoprotein (ZEBOV-GP) causes a lethal meningoencephalitis in
neonatal mice and showed that this could be used as BSL2compatible model to screen therapeutics for Ebola (18, 19). In
this study, we use a similar strategy to develop the ﬁrst symptomatic
BSL-2 mouse model. We show that when mice are challenged with a
pseudotyped GFP tagged vesicular stomatitis virus where the
surface glycoprotein is replaced with SARS-CoV-2 spike protein
(VSV-EGFP-SARS-CoV-2 (rVSV-SARS2-S)) they are infected in
an hACE2 dependent maner (6). Intranasal challenge with rVSVSARS2-S of K18-human ACE2 transgenic (hACE2tg) neonatal
mice results in lung and CNS lesions. The model, which is
uniformly lethal in mice, demonstrates a similar tissue tropism
and lethality as SARS-CoV-2 (Washington 2020 isolate) and can be
used to examine the immunoprotective effect of host immune
responses and therapeutics targeting the Spike protein. Further, the
model can be easily adapted to model emerging SARS-CoV-2 VOC.
Lastly, the model can be safely used in BSL2 facilities as this type of
construct has been used safely in vaccines (17, 19–21).

Severe Acute Respiratory Syndrome Corona Virus 2 (SARSCoV-2) is the causative agent of Corona Virus Disease- 2019
(COVID-19) which, since its emergence late in 2019, has caused
over 500 million cases of COVID-19 resulting in more than 5
million deaths and disrupted the world economy (1–3). SARSCoV-2 infections most frequently result in mild respiratory
symptoms, but 3-17% of cases develop severe pneumonia and
acute respiratory distress syndrome as well as cardiovascular, renal
and neurological manifestations including anosmia and ageusia,
which can last for months, and 1-8% of cases result in death (3, 4).
The severe morbidity and mortality of COVID-19 led to the
accelerated development of vaccines and therapeutics that were
ﬁrst implemented under emergency use authorization and then
licensed with unprecedented speed worldwide. Importantly the
emergence of SARS-CoV-2 Variants Of Concern (VOC) has
rendered some of these ﬁrst treatments ineffective and there are
lingering concerns regarding the emergence of variants resistant to
the protection conferred by monoclonal antibodies (mAbs) being
used as therapeutics and immunity elicited by the vaccines.
pt?>The majority of available COVID-19 vaccines and
therapeutics, including monoclonal and polyclonal antibodies,
target the spike protein in SARS-CoV-2 as this protein mediates
binding to the human cell-surface receptor angiotensinconverting enzyme 2 (hACE2) to facilitate viral entry and
infection of cells (1, 5). Neutralization potential as well as
antibody-dependent cellular cytotoxicity (ADCC) are thought
to be critical in predicting the efﬁcacy of antibodies to SARS-CoV2 (6, 7). Currently target selection is most frequently based on in
vitro neutralization assays, which can monitor cell entry but
unfortunately cannot model spread, release or transmission of
the virus, or examine drug pharmacokinetics/pharmacodynamics
(PK/PD), thus availability of an animal model can facilitate target
selection and preclinical studies (8–10). Indeed, the increased
capacity for formation of syncytia recently described for SARSCoV-2 VOC, underscores the need for animal models in
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Methods
Animals
B6.Cg-Tg (K18-ACE2)2Prlmn/J (stock 034860, hACE2tg) and
C57BL/6J breeding pairs were purchased from Jackson
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and exsanguination by transcardiac perfusion with PBS prior to
collecting the organs. Failure to gain weight compared to
C57Bl/6 mice, difﬁculty breathing, and activity level in the
cage were scored from normal (0,-/+) to severe (3, +++).
Clinical progression was assessed by observing the mice in the
cage as well as individually. Changes in behavior were recorded
and tallied. Per protocol, any animal that was unresponsive to
touch stimuli were considered moribund and euthanized. In
addition, animals that lost more than 20% of their body weight
were euthanized. Lastly, animals with symptoms that prevent
accessing nutrition, were euthanized as well. Tissues for gene
expression analysis were collected and ﬂash frozen in liquid
nitrogen and stored at -80°C until processing. Tissues for
immunohistochemistry were placed in 4% paraformaldehyde
(PFA) for ﬁxation for 24 hours. For histology samples, animals
were perfused with 4% PFA. A 25 G needle was inserted in the
trachea to expand the lungs with 4% PFA prior to collection. The
samples were stored in ﬁxative and sent to Histoserv labs
(Germantown, MD) for parafﬁn embedding, sectioning and
hematoxylin and eosin (H&E) staining.

Laboratory, bred and housed in sterile microisolator cages under
12-hour day/night cycle, in the speciﬁc pathogen-free, AAALAC
accredited animal facility of the U.S. Food and Drug
Administration (USFDA), Division of Veterinary Medicine
(Silver Spring, MD). Pups for study were the progeny of
hACE2+ male and female breeding pairs. As such, 75% of the
progeny were hACE2+ as per genotyping via real-time PCR
(primer/probe sequences available from Jackson Labs: https://
www.jax.org/Protocol?stockNumber=034860&protocolID=
38170). All ABSL-2 mice were handled in class II biosafety
cabinets. For all ABSL-3 experiments, breeding mice were
housed in ABSL-3 rated, isolated air cages with HEPA ﬁltered
output in animal rooms located in the USFDA BSL-3 facility. All
studies and procedures were approved by the FDA White Oak
Consolidated Animal Use and Care Committee (ACUC) and the
USFDA Institutional Biosafety Committee (IBC).

SARS-CoV-2 and rVSV-SARS2-S
virus preparation
SARS-CoV-2/human/USA/USA-WA1/2020 and an
infectious clone of this virus expressing EGFP (for
ﬂuorescence imaging) were obtained from ATCC through
Tony Wang (CBER, FDA). Variants of concern, including
SARS-CoV-2: B.1.1.7 (NR-54000), B.1.1.351 (NR-54008), P.1
(NR-54982) and B.1.617.2 (NR-55611) were acquired from BEI
Resources. VSV-eGFP-SARS-CoV-2 recombinant viruses
(rVSV-SARS2-S), expressing Spike proteins of the Wuhan
isolate (GenBank MN908947.3), B.1.1.7 (a), B.1.351 (b) and
P.1 (g) and B.1.617.2 (D) were prepared by Dr. Sean Whelan (6).
VSV expressing the Wuhan isolate Spike encodes the full length
Spike gene, which acquired a mutation that truncated the
cytoplasmic tail by 21 amino acids, as described; the Spike genes
of B.1.1.7, B.1.351, P.1 and B.1.617.2 viruses were cloned to truncate
the ﬁnal 21 amino acids of the Spike gene prior to rescue. All viruses
were propagated (fewer than 3 passages) in Vero E6 cells to generate
master stocks. The stocks were titrated (TCID50) on Vero E6 cells
and working stocks were aliquoted and stored at -80°C.

Virus quantiﬁcation
Absolute quantiﬁcation was determined using full length SARSCoV-2 spike RNA transcribed from pcDNA 3.1- SARS2-Spike
plasmid using the T7 Megascript transcription kit (ThermoFisher,
Carlsbad, CA). pcDNA3.1-SARS-2-Spike was a gift from Fang Li
(Addgene plasmid #145032). The number of copies transcribed was
calculated based on absorbance at 260 nm. One-step reverse
transcription (RT)-real time qPCR was performed using the RNAto-Ct kit (Thermoﬁsher, Carlsbad, CA). A 10-fold serial dilution of
transcribed RNA was used to generate a standard curve for
quantiﬁcation. Total RNA was isolated from tissues homogenized
in Trizol (Invitrogen) per manufacturer’s instructions. One
microgram (µg) of isolated total RNA from infected tissues was
analyzed in each reaction. This assay ampliﬁes the region
corresponding to nucleotide 2442-2500 of SARS-CoV-2 spike
gene. Forward primer: GAGGTCATTTATTGAAGATCTACT;
Reverse Primer: GCAATCACCATATTGTTTGAT; Probe:
AAAGTGACACTTGCAGATGCTGGCTT. Primers were
synthesized through Genescript (Piscataway, NJ). Cycling
conditions: 48 °C for 15 min, 95 °C for 10 min, 40 cycles of 95 °C,
15 sec and 60 °C for 1 min. Data was collected and analyzed using an
Applied Biosystems Viia7 real-time instrument with QuantStudio
Software (ver. 1.6).
Tissue culture Infectious Dose (TCID) 50 assay: Infectious
SARS-CoV-2 and rVSV-SARS2-S levels in organ homogenates
(half brain or two lung lobes in 1 mL of culture medium) from
perfused mice were measured on Vero E6 monolayers using an
end-point dilution assay as previously described; TCID50 values
were calculated using infectivity calculator based on Reed and
Muench method (22, 23).

Virus infection and organ collection
Neonatal hACE2tg pups Post natal day 1 (P1) or Post natal
day 5 (P5) as indicated in each ﬁgure, were infected with 1.0 x
105 TCID50 or the indicated challenge dose of virus by intranasal
inoculation. A 10 ml pipet tip was used to administer the virus
preparation to the nostrils and pups inhaled the droplets (5-10 ml
total volume). Due to the young age of the pups, minimal
restraint and no anesthesia was required for inoculation. The
female breeder was left in the cage throughout the experiment to
provide nourishment and care to the pups. At the indicated
times post-infection, mice were euthanized by CO2 asphyxiation
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using GraphPad Prism (ver 9.x). Dendrograms were created in R
(v 4.1) (24) using the iHeatmapr (25) library.
Pathway analysis: Gene expression proﬁle in the brains of
mice infected with SARS-CoV-2 (red) and rVSV-SARS2-S (blue)
was explored using GAGE analysis (26) on GO (Gene ontology)
pathways. Stat.mean (bars) is the average of individual statistics
for the gene set of each pathway, with bars representing direction
and magnitude of the pathway. The Q-values (lines) show the
False Discovery Rate (FDR) adjustment of the global p-value
derived from individual tests as performed by GAGE analysis.
Shown is a curated list of the most up and down-regulated
pathways, plotted using the ggplot from the tidyverse packages
(27). For the dendrograms, the signal was standardized for all
sample’s log-scaled counts across a given gene.

Neutralization assay
Vero E6 cells were seeded at 2-4 x 104 cells/well in 96 well
plates and incubated at 37°C to reach 70-80% conﬂuency.
Antibody samples were incubated with 1.0 x 103 TCID50 of
virus for 1 h at 37°C. Antibody-virus complexes were added to
Vero E6 cell monolayers in 96-well plates and incubated at 37°C
for 1 h. Subsequently, the cells were washed, and incubated for
12-16 h in fresh media. Neutralizing ability of antibodies was
assessed by monitoring levels of GFP positive cells in the infected
wells and compared to untreated control wells using an Olympus
IX-81 microscope. GFP levels were monitored using Victor X3
multimode plate reader. Anti-Spike protein (RBD) mAb CV30
(mouse IgG1, kappa) was obtained from Absolute antibody
(Boston, MA, product code: Ab02019-1.1). Heat inactivated
plasma samples were obtained from Washington Adventist
Medical Health care and Shady Grove Adventist hospital.
Plasma from 3 donors who recovered from SARS-CoV-2
infection in April-May 2020 before the emergence of VOCs
and had high neutralizing antibody titers were pooled and used
as Human Immune plasma for the neutralization assay and
protection studies in mice.

Immunoﬂuorescence
immunohistochemistry and histology
One hemisphere of the brain and both lungs from infected
and uninfected animals were ﬁxed with 4% PFA and sent to
Histoserv (Germantown, MD), where the tissues were embedded
in parafﬁn and sectioned. Sections were stained with
hematoxylin and eosin (H&E) by Histoserv, and unstained
sections returned to the lab for immunohistochemical staining.
These sections were deparafﬁnized using xylenes, and rehydrated
in graded ethanol (100%, 95%, 70%, 50%). Sections were rinsed
in ddH2O and underwent antigen retrieval in 0.1M sodium citrate
(pH 9.0) for 8 minutes, then allowed to cool at RT for an additional
10 minutes and washed with PBS. Endogenous peroxidase activity
was removed by treating the sections with 3.7% H2O2 for 30
minutes. After washing with PBS the tissue sections were
permeabilized using 0.5% Triton X-100 in PBS for 60 minutes at
RT and blocked with 5% normal goat serum (NGS) and 1% bovine
serum albumin (BSA) in PBS + 0.05% Triton X-100 for 1 hour.
Staining was performed using a three-step detection, with: antiSARS-CoV-2 Spike RBD rabbit polyclonal antibody (Sino
Biologicals, Wayne, PA, Cat #40150-T30) for 2 hours at RT,
followed by a biotinylated anti-rabbit IgG for 1 hours at RT and
Streptavidin-HRP for 30 minutes (Vector Laboratories,
Burlingame, CA). Immunostaining was detected using
ImmPACT DAB peroxidase substrate and washed as per
manufacturer’s instructions ((Vector Laboratories, Burlingame,
CA). Stained sections were dehydrated in graded ethanol (70%,
95%, 100%), cleared with histology grade xylenes, and mounted
with DPX mountant (MilliporeSigma, St. Louis, MO).
To characterize the CNS infection by IF-IHC, one
hemisphere of brains from infected and uninfected animals
were placed in freshly prepared 4% paraformaldehyde (PFA)
solution (in 1 x PBS pH 7.4) immediately after extraction (RNA
was extracted from the other hemisphere as described above).
After 24 hours of ﬁxation at 4°C, the tissue was transferred to
30% sucrose in 1 x PBS for cryoprotection. The brains remained in

Gene expression analysis
using Nanostring
Mouse Immunology Panel (Nanostring Technologies,
Seattle, WA) consisting of 561 genes including 15 internal
reference genes was used. The complete gene list for the
nCounter Mouse Immunology panel used in this experiment is
available at www.nanostring.com. Reporter and Capture probes
were mixed with 100 ng of total RNA (20 ng/ml in molecular
grade, ultra-pure ddH2O) isolated from the CNS and lungs of
uninfected, SARS-CoV-2 infected and rVSV-SARS2-S infected
hACE2tg mice. RNA and probes were hybridized for 18 hours
prior to processing and data acquisition using the Nanostring
MAX acquisition system, using ultra-sensitive mode and
counting 280 ﬁelds of view (FOV) per sample. These data
were normalized to internal controls and housekeeping genes
in the panel as per manufacturer’s instructions. For Figure 4A
(left panel) as well as for Supplementary Figures 4 and 7, genes
and samples were sorted using hierarchical clustering and
plotted using the iheatmapr library. Note that in these ﬁgures,
log-scale counts for each of the samples were normalized within
each gene by calculating their Standard Score, which was deﬁned
as the difference between the logscale counts sample and the
average logscale count divided by the standard deviation of the
logscale counts for that same gene. Thus, the colors ranging from
white to green indicate the relative expression of the gene, rather
than suggest up or down regulation. In radial graphs (Figure 4B),
gene expression is expressed as fold-change in gene expression,
relative to age-matched uninfected control animals. These data
were analyzed using Nanostring nSolver (ver. 4) and plotted
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30% sucrose at 4°C until they sank in the solution (typically ≥ 24
hours). Sucrose embedded tissue was mounted in TissueTek O.C.T
(Sakura-Finetek, Torrance, CA) and frozen. The brains were stored
at -80°C until sectioned. Sagittal sections (25 mm thick) were cut
using a Leica CM1900 cryostat at a chamber temperature of -20°C
(Leica Biosystems, Buffalo Grove, IL) and mounted onto
Superfrost-Plus Gold microscope slides (Fisher Scientiﬁc,
Carlsbad, CA). Mounted sections were stored at -20°C until
staining. Prior to staining, sections were warmed to room
temperature (RT) to dry, then immersed in phosphate buffered
saline (PBS). Antigen retrieval was then performed as described
above. The sections were then washed with PBS and permeabilized
using 0.5% Triton X-100 in PBS for 60 minutes at RT; then blocked
and autoﬂuorescence quenched with 5% normal goat serum and
1% bovine serum albumin (BSA) in PBS + 0.05 % Triton X-100 and
0.3M Glycine for 2 hours. Primary antibodies used include: antiSARS-CoV-2 Spike RBD rabbit polyclonal antibody (Sino
Biologicals, Wayne, PA, Cat #40150-T30), neuroﬁlament heavy
chain cocktail (SMI31, Cat # 801601) and SMI32 mAb (Cat #40150T30), Biolegend, rat anti-CD45 (BD Biosciences, Clone 30-F11,
cat# 553076), rabbit anti-Ionized calcium-Binding Adapter
molecule-1 (Iba-1) (Wako, Cat#019-19741). Endogenous EGFP
expressed by the viruses was detected without additional staining.
Tissue sections were incubated overnight in a humidiﬁed chamber
at room temperature with primary antibodies diluted with 1% BSA
in PBS + 0.5% Triton X-100. The slides were then washed with PBS
+ 0.05 % Triton X-100 followed by 1 x PBS and treated with the
appropriate AlexaFluor (AF)-conjugated secondary antibodies
(raised in goat) (ThermoFisher, Carlsbad, CA), diluted in 1%
BSA in PBS + 0.05% Triton X-100 for > 120 min at RT. All IFIHC sections were mounted with Pro-Long Diamond anti-fade
mounting media containing DAPI (ThermoFisher, Carlsbad, CA).
Sections were imaged using an Olympus VS-120 virtual slide
microscope (Olympus LSS) using a 20x or 40x objective lens. AFlabelled antibodies and endogenous ﬂuorescence were detected at
emission wavelengths: 405 nm (DAPI), 535 nm (Alexa-ﬂuor 488,
EGFP), 605 nm (Alexa-ﬂuor 568) and 650 nm (Alexa-ﬂuor 647).
Regions of interest were captured using VS-Desktop software (ver
2.9, Olympus LSS). For confocal imaging, images were acquired
using a Zeiss LSM 880 confocal microscope, using 405 nm (DAPI),
488 nm (AF488, EGFP), 561 nm (AF568) and 633 nm (AF647)
excitation lasers. Optimal ﬂuorescence detection settings were
determined and applied to all sections equally. Images were
acquired using the Zeiss Zen software. Maximum intensity
projections of acquired Z-stacks were compiled using Zeiss Zen
and/or ImageJ + Fiji (NIH) software (28). Images were compiled
into ﬁgures using Adobe Photoshop CS software.

Two-tailed unpaired Student’s t test or 1-way ANOVA with
Dunnett’s multiple comparisons were used as appropriate.
Statistical analyses were conducted with GraphPad Software
(version 7.03). P < 0.05 was considered statistically signiﬁcant.
Graphs show Mean and SD.

Results
The model: SARS-CoV-2 spike
pseudotyped VSV infects human ACE2
transgenic mice and causes disease
comparable to SARS-CoV-2 infection
Previous studies established that K18-hACE2 transgenic
mice (hACE2tg), in which hACE2 expression is driven by the
epithelial cell-speciﬁc human cytokeratin 18 (K18) promoter
and expressed in airway epithelial cells, as well as brain, liver,
kidney, spleen, heart, and intestine renders mice susceptible to
SARS-CoV-2 infection, however these challenge studies have to
be performed in BSL3 labs (13, 29–32). To develop a BSL-2
mouse model suitable to test therapeutics targeting SARS-CoV-2
spike protein, we challenged hACE2tg mice (4-6 weeks old) with
a replication-competent recombinant enhanced green
ﬂuorescent protein tagged VSV where the native glycoprotein
was replaced by SARS-CoV-2 spike protein (rVSV-SARS2-S).
Neither intramuscular (IM) nor intranasal (IN) infection of
adult hACE2tg mice with rVSV-SARS2-S (up to 1 x 105
TCID 50 /mouse) resulted in weight loss or symptoms
(Supplementary Figure 1) and no viral RNA was detectable in
blood at 3 dpi, or blood, liver, lung or brain homogenates at 8
dpi. This suggests that rVSV-SARS2-S could not be used to
model COVID-19 in adult hACE2tg mice.
Neonatal mice have increased susceptibility to viruses and
develop symptomatic infections when challenged with Alpha-,
Arena- and Flavi-viruses, even when the adults of the same strain
are resistant (18, 19, 23, 33–35). As expected, neonatal hACE2 tg
mice succumbed following a SARS-CoV-2 (102-105 TCID50
Washington 2020 isolate, IN) challenge in a dose-dependent
manner (Figures 1A–D and Supplementary Figure 2F) and high
titer virus were evident in the lungs and brain of mice challenged
IN with 105 TCID50 as determined by viral RNA levels and
TCID50 (Figure 1E). To determine whether VSV-SARS2-S
would cause a symptomatic infection in neonatal hACE2tg
mice, P1 mice were challenged with rVSV-SARS2-S (102-105
TCID50 IN; Figures 1A–D and Supplementary Figure 2C).
While the disease progression was slower than with SARS-CoV2, all mice showed reduced weight gain starting by 3 dpi,
developed dyspnea and reduced exploratory activity by 6DPI,
and succumbed by 9 dpi (Figures 1B–D). Assessment of viral
distribution in the hACE2tg mice showed that both models had
higher levels of viral RNA and infectious virus in the brain, and
lower but consistent levels in the lungs (Figure 1E). Viral RNA

Statistics
Weight gain was analyzed using a Kruskal Wallis test.
Survival experiments were analyzed using the log-rank test.
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levels in blood, liver, spleen, heart, kidney, and small intestine of
mice challenged with rVSV-SARS2-S were negligible and
infectious virus was not detectable by TCID 50 assay
(Supplementary Figure 3A). Indeed, these were not different
from those reported in adult hACE2tg mice (29, 36), although
the relative viral load can change signiﬁcantly depending on the
day it is assessed (32). Although infectious virus was only detected
in the brain and lungs of neonatal hACE2Tg mice, expression of
human ACE2 was seen in all the tissues tested (Supplementary
Figure 3B) and the expression pattern was similar to that found in
adult hACE2Tg mice (30, 32). Neonatal C57BL/6J mice
challenged with SARS-CoV-2 or rVSV-SARS2-S showed no
change in weight or lethality and no virus was recovered at P4
or P9. Surprisingly, even neonatal Interferon alpha and beta
receptor 1 Knock-out mice (C57BL/6J-IFNAR KO) showed no
weight change or symptoms indicating that rVSV-SARS2-S, like
SARS-CoV-2, requires the presence of hACE2 to infect cells
(Supplementary Figure 2). Concordantly, in-vitro studies with
BHK-21 cells demonstrated that rVSV-SARS2-S requires the
presence of hACE2 to infect cells (Supplementary Figure 3C). In
summary, the comparable tissue tropism, disease phenotype and
lethality of SARS-CoV-2 under BSL-3 conditions and the rVSVSARS2-S infection suggested that this is a viable surrogate model
for SARS-CoV-2 spike mediated infection under BSL-2 conditions
to test therapeutics and vaccines directed to the spike protein.

A

B

D

E

Lung infection
We next compared the infection and response in the lungs.
Given the difference in disease progression, studies were
performed by challenging with SARS-CoV-2 at P5 and with
rVSV-SARS2-S at P1 and then collecting tissues for both models
on P8, when most animals were symptomatic but not
moribund (Figure 1A).
In both models, on P8, infected mice showed minor discrete
lesions characterized by small dispersed inﬂammatory foci and
alveolitis with minor polymorphonuclear (PMN) leukocyte
inﬁltration PMN inﬁltration and blood extravasation into the
alveolar space (Figure 2A). Consistent with this there was a
moderate increase in the mRNA expression of genes coding for
interferon responses (Ifna1, Ifna2, Iﬁh1, Irf7, and Ptpn22) as well
as platelet markers CD36 and Itga2b. However, while the changes
in mRNA expression for proinﬂammatory signals were modest,
the increase in Il6ra and Il11ra1, was not paired with an increase
in Il6st and there was no signiﬁcant increase in Il6 or Tnf
indicating that the inﬂammation in the lungs is minor
(Figure 2B, Supplementary Figure 4). Of note, the increased
level of Fkbp5 known to regulate NFkB and RIG-I signaling
could contribute to the muted response (37). Concordant with the
minor inﬂammatory response in lungs, there was no signiﬁcant
signal of inﬂammation in sera (Supplementary Figure 5).

C

FIGURE 1

Infection of hACE2tg mice with rVSV-SARS2-S or SARS-CoV-2 results in infection of lungs and brain and leads to lethal disease. (A) Schematic
representation of the timeline of SARS-CoV-2 and rVSV-SARS2-S infection and disease course. Note that mice were challenged on P1 with
rVSV-SARS2-s or on P5 with SARS-CoV-2 but tissues were collected on P8 for both groups. (B) Symptoms in hACE2tg mice infected with SARSCoV-2 and rVSV-SARS2-S viruses. (C, D) Control mice (C57BL/6J, black, circle n > 10, overlapping for both viruses) or hACE2tg mice (blue and
red) were challenged intranasally with 105 TCID50 of SARS-CoV-2 (red squares, n > 10) or rVSV-SARS2-S (Blue triangles, n > 10) and monitored
for weight gain (C) or survival (D). (E) Viral RNA titers in lung and brain homogenates of mice infected with rVSV-SARS2-S infected (n = 5/group)
and SARS-CoV-2 infected (n = 5-8/group) as assessed by SARS-CoV-2 spike protein speciﬁc Taqman assay and infectious virus measured by
TCID50 assay in Vero E6 cells. Figure shows titers per ug of RNA (qRT-PCR) or half-organ (TCID50). Graphs show mean ± SD; *denotes weight
difference between rVSV-SARS2-S and uninfected mice at P8 (p<0.05) as measured by Krusckal-Wallies non parametric ANOVA.
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genes consistent with viral encephalitis (Figure 4). Pathway
analysis showed both models inducing strong upregulation of
genes linked to innate immune, type I interferon, antiviral and
chemokine activity, as well as downregulation of genes in the
tissue remodeling, cell development, erythropoiesis, and
neurogenesis (Supplementary Figure 8). More speciﬁcally,
there was strong upregulation of Irf-7, Irf-1, Stat-1, Stat-2,
Ddx58 and Iﬁh1 as well as Iﬁ35, Iﬁt2, Iﬁ204, Bst-2 and Irgm-1
indicative of a strong type I interferon response to the virus while
increased transcript levels of complement factors C3, C4a and
Cfb suggests complement pathway activation (Figure 4).
Elevated levels of Ptprc (Cd45) are consistent with an increase
in inﬁltrating cells and the increase in Cxcl10, Ccl5, Ccl12 and
Ccl2 as well as B2m, MHC class I and class II, Tap1, Tapbp, Ctss,
and Psmb9 indicate increased antigen processing and
presentation. However, a weak upregulation of Il1, Il12 and
Tnf, and increased expression of Il1rn, Socs1, CD274 (Pdl1) and
Lilrb3/4 suggests local immune regulation (Figure 4 and
Supplementary Figure 7. Thus, while the overall pattern of
mRNA expression in the CNS elicited by SARS-CoV-2 and
rVSV-SARS2-S were comparable, the magnitude of the response
was higher in SARS-CoV-2 infected mice.

CNS infection
In both models, the viral load was highest in the brains.
Visualization of the virus at P8 using GFP-tagged virus showed
signiﬁcant spread of the virus throughout the brainstem,
subcortical nuclei, mid and hind brain in both models
(Figure 3A). In the cortex, there was evidence of virus in
neurons and neurites spanning multiple layers (Figure 3A).
Colocalization with neuroﬁlament (NF+) suggests that
neurons were infected while the surrounding microglia (Iba+)
were uninfected but display activated morphology (Figure 3A
and Supplementary Figures 6A, B). Further, in both models
there was an increase in degenerative neurons, including in the
olfactory bulbs (Supplementary Figure 6A) suggesting a possible
path for the virus to enter the CNS. Of note, at P8 the virus in the
brains of SARS-CoV-2 infected mice was more broadly
distributed compared to those of rVSV-SARS-CoV-2-S
infected mice (Figure 3A). Differences were also notable in
cerebellum where SARS-CoV-2 infects Purkinje cells, while
rVSV-SARS2-S infected neurons in the molecular and
granular layers as well as in the white matter tracts
(Supplementary Figure 6A). Associated with the broader virus
distribution, there is a greater inﬁltration by CD45+ immune
cells in the CNS of SARS-CoV-2 infected mice, which was
conﬁrmed by H&E (Figure 3B) and by the higher expression
of Ptprc (CD45) in the infected CNS (Figure 4). These
differences were consistent with the accelerated disease
progression in the SARS-CoV-2 model.
Unlike the lungs, the gene expression screen for the CNS
from both models harvested on P8 (3 dpi for SARS-CoV-2 and 7
dpi for rVSV-SARS2-S) showed a clear change in mRNA
expression patterns with an upregulation of inﬂammatory

A

Testing therapeutic antibodies
Antibodies targeting the spike protein are being used to treat
infected patients with high clinical risk. The neutralizing
capacity of these antibodies is often tested in vitro by premixing the antibodies with a non-replicating pseudotype virus
and then measuring cell entry into susceptible cells such as Vero
E6. The use of replicating viruses can improve the assessment as

B

FIGURE 2

Lung infection in mice challenged with SARS-CoV-2 and rVSV-SARS2-S viruses. (A) Left panels: Immunohistochemistry for Spike RBD. Red
arrows indicate SARS-CoV-2 infected cells. Blue arrows indicate rVSV-SAR2-S infected cells. Right panels show H&E staining of lungs (100 and
600X). Green arrows indicate inﬁltrating immune cells (image representative of 6 mice/group). (B) Fold-change in selected genes from the lungs
of SARS-CoV-2 and rVSV-SARS2-S (n=8) infected mice at P8 compared to age-matched uninfected control mice as assessed using Nanostring
technology (nCounter Mouse Immunology Panel). The complete gene expression proﬁle can be found in Supplementary Figure 4.
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B

FIGURE 3

Neuroinvasion and tissue damage in SARS-CoV-2 and rVSV-SARS2-S infected mice. (A) Top: Whole brain, sagittal section of P8 mice infected
with SARS-CoV-2 and rVSV-SARS2-S viruses. Replicating virus labeled with GFP (green), Neuroﬁlament (Red), and nuclei with DAPI (blue). Scale
bar:1mm. Bottom: Confocal images of cerebral cortex stained with green (GFP expressed by infecting virus) and Red Indicating: CD45
(inﬁltrating immune cells), Iba-1 (microglia) or NF (neurons) (N = 6). Scale bar: 25mm. (B) H&E and Spike RBD IHC from infected regions of the
CNS. Top: wide-ﬁeld H&E. Middle: high magniﬁcation H&E. Black arrows indicate degenerating neurons. Bottom: IHC staining for Spike RDB.
Red arrows indicate SARS-CoV-2 infected cells. Blue arrows indicate rVSV-SAR2-S infected neurons in these regions (N = 6). Scale bar: 100 and
20 mm.

interaction with ACE2 expressing cells and a useful tag to
monitor virus spread in tissues.
SARS-CoV-2, like other RNA viruses, is prone to genetic
evolution, and even single amino acid changes can drastically
affect a virus’s ability to bind ACE2 or evade the immune system
(5, 38). Over the last year, several variants of concern have emerged
with mutations in the RBD that enhance transmission and/or
virulence (39–41). A critical concern in developing therapeutics
targeting SARS-CoV-2 is the possibility that they will lose efﬁcacy as
the virus mutates. Indeed, the clinical efﬁcacy of several approved
mAbs against the original Washington 2020 isolate of the SARSCoV-2 was reduced when treating patients infected with the
emerging VOC (10, 42, 43). Thus, the emergence of each VOC
requires reassessment of the efﬁcacy of the therapeutics targeting
the spike protein. To demonstrate that this model can be adapted to
test emerging VOC, we used four different rVSV-SARS2-S viruses
expressing the spike protein of B.1.1.7 (alpha, a), B.1.351 (beta, b),
P.1 (gamma, g) or B.1.617.2(delta, D) and compared the lethality
with the corresponding wild type viruses under BSL-3 conditions.

it reﬂects not only entry, but replication and release of the virus
from the cells. Here, we tested human immune plasma (from
patients who recovered from SARS-CoV-2 infection) and antiSARS-CoV-2 spike protein RBD domain monoclonal antibody
(CV-30). Both antibodies neutralized rVSV-SARS-CoV-2-S virus
(Figure 5A). Availability of animal models infected with replicating
virus can provide evidence of in vivo efﬁcacy of these therapeutics.
As shown in Figure 5B treatment with CV-30 (2mg/g) administered
intraperitonealy conferred 100% protection from lethal challenge
while human immune plasma (5mL/g) failed to protect mice from
lethal infection (Figure 5B). The difference in bioactivity in vivo
correlated with the relative differences in neutralizing titer of the 2
preparations. However, the same dose of CV-30 mAb treatment
post-infection did not rescue hACE2tg mice from lethal infection in
either model (Supplementary Figure 9). Importantly, the effect of
the different antibodies tested prophylactically or therapeutically
mirrored each other in SARS-CoV-2 and rVSV-SARS2-S models,
demonstrating that the BSL-2 model can be a suitable option to test
antibodies designed to prevent SARS-CoV-2 spike protein
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FIGURE 4

Gene expression in the brain of mice infected with SARS-CoV-2 and rVSV-SARS2-S. (A) Nanostring mouse immunology panel. Heatmap shows
gene expression (normalized counts as described in materials and methods) in the brain of SARS-CoV-2 infected (red), rVSV-SARS2-S infected
(blue) and uninfectected control (green). Each column in the heatmap represents an individual mouse (n = 4-8/group; P8) and the blue, red and
green lines on the right depict the average gene expression. The complete labeled Nanostring panel of 547 immunology-related mouse genes
used for analysis is presented in Supplementary Figure 7. (B) Changes in gene expression (selected) in brain tissue of SARS-CoV-2 (red) or rVSVSARS2-S (blue) infected mice relative to age-matched uninfected mice. Data is presented as fold change in infected, compared to average of
uninfected age-matched controls. Note that gene expression in (A) is reported as normalized absolute counts and gene expression in (B) is
reported as fold increase over age-matched uninfected control mice.

virus can be used to infect hACE2tg mice and model SARS-CoV2 infections under BSL-2 conditions. Importantly, this virus
lacks the VSV glycoprotein that mediates cell entry, so the tissue
tropism is solely mediated by the engineered Spike protein, as
demonstrated by the need for expression of hACE2 to infect
BHK-21 cells and selective infection of hACE2 expressing mice
(Supplementary Figure 3C). Although neonatal K18-hACE2tg
mice show broad distribution of the ACE2 receptor
(Supplementary Figure 3B), intranasal challenge with SARSCoV-2 or rVSV-SARS2-S results in infection of the brain and, to
a lesser extent, the lungs. Both challenges result in similar tissue
distribution and levels of virus, with minor lung lesions and a
lethal meningoencephalits. Further, both challenges increased
the expression of a common subset of genes in the CNS, however
the disease course is longer (8 vs 4 days) and the relative
inﬂammatory gene expression levels are lower in rVSVSARS2-S compared to SARS-CoV-2 infected mice. Lastly,
testing of different mAbs targeting the spike protein resulted
in similar degrees of protection in both models. Thus, this model
can be used to test potential countermeasures targeting the
SARS-CoV-2 spike protein in BSL-2 containment.
Importantly, over the last year, several VOCs have emerged
with mutations in the RBD that enhance transmission and/or

As seen in Figure 5C, neonatal hACE2tg mice can be lethally
infected with 1 x 104 TCID50 of rVSV-SARS2-SB.1.1.7, rVSVSARS2-SB.1.351, rVSV-SARS2-SP1, or rVSV-SARS2-SB.1.617.2 at P5.
Interestingly, both the mice infected with VOC and those infected
with VSV expressing the Spike protein of the 4 VOCs showed
accelerated death relative to those infected with SARS-CoV-2 (1 x
104 TCID50) and rVSV-SARS2-S (1 x 105 TCID50). As the only
difference between these viruses is the spike protein, this
underscores the critical role of the spike protein in disease
severity and suggests that changes in the spike are sufﬁcient to
confer increased virulence, further studies using this model may
facilitate our understanding of the role of spike protein in
progression and dissemination of disease. Together, these results
demonstrate that the VSV-based model can be easily adapted to
emerging variants of concern and can be a useful tool to screen
novel therapeutics and combinations to control new VOC as
they emerge.

Discussion
This report shows that a replicating VSV pseudovirus where
the VSV-G is replaced by the Spike protein of a SARS-CoV-2
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FIGURE 5

In vitro neutralization and in vivo modeling of antibodies to SARS-CoV-2 Spike bioactivity. (A) Neutralizing activity of an anti-SARS-CoV-2 RBD
domain mAb (Black square) and human immune serum pooled from donors recovered from SARS-CoV-2 infection (green triangles) were tested
in a micro neutralization assay on Vero E6 cells infected with replicating rVSV-SARS2-S. (B) Human ACE2tg mice were treated intraperitoneally
with 2 µg/g of CV30 mAb (black line) or 5 µl/g of human immune serum (green line) 24 hours before being intranasally infected with 105 TCID50
of rVSV-SARS2-S (n ≥ 7) or SARS-CoV-2 and monitored for survival (n ≥ 7/group). Untreated, age-matched SARS-CoV-2 (red line) and rVSVSARS2-S (blue line) Infected hACE2tg mice were used as controls. Differences in survival were assessed using a Log Rank Mantel Cox test. ** p <
0.005. (C) Human ACE2tg mice were infected at P5 with 104 TCID50 SARS-CoV-2 or 105 rVSV-SARS2-S (104 TCID50 of rVSV-SARS2-S shown in
Supplementary Figure 2C), or with 104 TCID50 of SARS-CoV-2 Variants of Concern (SARS-CoV-2a, SARS-CoV-2b, SARS-CoV-2gSARS-CoV-2D) or
VSV pseudotype virus expressing the corresponding SARS-CoV-2 spike protein and monitored for survival (n = 6-13 mice/group).

infection extends to neonatal mice (14, 44). This is different
from challenges with the parental VSV or from rVSV expressing
the Ebola Zaire glycoproteins as previously shown (18). The
increased susceptibility of neonatal mice to viral infections is
well established (18, 23, 34, 35, 45, 46). This extends to
coronaviruses where reports show the acquisition of virulence
in young, but not aged, mice through serial passage of SARSCoV Urbani strain (47). Consistent with this, the disease
progression in neonatal mice challenged with SARS-CoV-2
was faster and lethality more consistent than that reported in
adults (14, 29, 48). Surprisingly, although SARS-CoV-2 can lead

virulence, and critically, can bypass the host’s memory response
and reduce the effectiveness of therapeutic antibodies or vaccines
that target the spike protein. Switching the spike protein on the
VSV pseudotype virus allows for modeling existing or even
potential mutations of the virus providing an important tool to
address emerging variants.
In-line with reports showing adult C57BL/6J mice are
resistant to SARS-CoV-2 infection, neither SARS-CoV-2 nor
rVSV-SARS2-S were able to infect neonatal C57BL/6J mice even
when deﬁcient in type I interferons indicating that the absolute
requirement for spike-hACE2 interaction for establishing
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which can infect neonatal and adult B6.Cg-Tg (K18-ACE2)2Prlmn/
mice, rVSV-SARS2-S infected neonatal but not adult B6.Cg-Tg
(K18-ACE2)2Prlmn/mice. The increased susceptibility of neonatal
mice is not unique (23, 35, 54). The increased susceptibility in
neonates does not appear to be not due to hACE2 distribution,
which is similar between neonatal and adult B6.Cg-Tg (K18-ACE2)
2Prlmn/J mice (Supplementary Figure 3B), but could be secondary
to immature innate immune responses in neonates allowing
unchecked virus proliferation. Of note, previous studies have
shown that neonatal mice can produce type I interferons in
response to infection (18), and treatment of adult tg mice with
1600 ng of anti-IFN antibodies (SC) did not render them
susceptible as no virus could be detected at 2 or 6 days post
infection indicating that an immature interferon response alone is
not sufﬁcient to confer susceptibility. Other factors such as the
integrity of the blood brain barrier, the frequency of immature
replicating cells, or the level of other anti-viral factors such as
cholesterol 25-hydroxylase (CH25H) expression (28), which has
been shown to inhibit VSV and SARS-CoV-2 virus-cell fusion may
contribute to the difference is susceptibility between neonates and
adults (55). Given that cell tropism is determined by the spike
protein, the difference in susceptibility of adult B6.Cg-Tg (K18ACE2)2Prlmn mice to challenges with SARS-CoV-2 or rVSVSARS2-S is intriguing. These could be linked to differences in
viral ﬁtness, or potentially to small differences in binding afﬁnity
of the spike to the ACE2 receptor associated to the 21 amino acids
that were excluded from the spike protein to allow for efﬁcient virus
release. Of note, despite these potential differences in the spike
protein between SARS-CoV-2 and VSV-SARS2-S, the expression of
spike by the VSV, allows for an induction of immune responses
capable of providing protection against SARS-CoV-2 (Israely et al,
2020) suggesting presentation of the spike protein on the viral
membrane with antigenic similarity to SARS-CoV-2. This is
consistent with the similar levels of protection conferred by the
antibody preparations with both viruses.
Although previous studies have shown that SARS-CoV-2
infection resulted in neuro invasion, this is the ﬁrst report that
demonstrates a SARS-CoV-2 spike protein pseudotyped, replication
competent recombinant virus from a peripheral infection can spread
to the CNS and result in productive infection of neurons.
Understanding of the susceptibility of terminally differentiated cell
types like neurons, astrocytes and microglia are difﬁcult and often
depend on ex vivo or in vitro culture of these cell types and use
antigenic staining. This study uses an in vivo system and an enhanced
GFP tag that is dependent on cellular replication to demonstrate
infection of neurons and lack of replication in microglia. Neuronal
infection, microglial activation and inﬁltration of immune cells are
common to both viruses as is the increase in degenerative neurons.
Unlike the lungs, the response to SARS-CoV-2 and rVSV-SARS2-S
in the CNS is robust and characterized by the expected signiﬁcant
expression of genes linked to the type I interferon, complement
activation, inﬂammation as well as markers of cellular inﬁltration
(Supplementary Figure 7). However, the increase in regulatory

to severe respiratory distress and lung pathology in adult mice,
the same does not occur in neonates, where the disease affects
primarily the CNS, regardless of whether they are infected with
SARS-CoV-2 or rVSV-SARS2-S (29, 36). This could be partly
due to the mode of infection, as intranasal infection in neonates
does not entail anesthesia, to differences in the lung’s innate
immune system, or the rapid lethality of the CNS infection (49).
Indeed, the low level of infection in lungs compared to CNS
suggests the possibility of virus uptake via the olfactory bulb
rather than secondary to colonization of the lungs and
hematogenous spread. In support of this, there is detectable
virus in the olfactory bulb and the olfactory tract
(Supplementary Figure 6A) as recently shown for SARS-CoV2 and previously shown for SARS-CoV (50, 51). While no virus
is evident in the olfactory bulb of rVSV-SARS2-S infected mice,
this may be due to the timing of the tissue harvest relative to
infection (7 dpi) as the presence of degenerate neurons suggest
previous infection in the tissue. Thus, it is possible that the
encephalitis, affecting particularly the brain stem and mid brain
leads to lethality before high levels of virus in the lung are
achieved. This would be consistent with the low level of infection
and inﬂammation observed in the lungs and appears more likely
than the low viral titers in lungs being secondary to a robust host
immune response in neonates. Alternatively, it is also possible
that pathogen-mediated host immune suppression contributes
to the mild pathology. The lack of increase in inﬂammatory
markers in serum late in disease course is in-line with the
reduced virus RNA and inﬂammation seen in the lung.
Vesicular stomatitis virus (VSV), a prototype of the
Rhabdoviridae family, contains a single surface glycoprotein (G)
that is required for attachment to cells and mediates membrane
fusion (52, 53). In the rVSV-SARS2-S model, the surface G was
replaced by the SARS-CoV-2 spike protein. Several lines of evidence
demonstrate that the spike-hACE2 interaction is responsible for the
attachment and infection of cells: 1) In vitro, rVSV-SARS2-S can
infect BHK21 cells stably transfected to express hACE2 receptor,
but not the parental cells that do not express the receptor
(Supplementary Figure 3C); 2) Infection of cells expressing the
hACE2 receptor can be blocked by antibodies that target the spike
protein (Figure 4A). 3) rVSV-SARS2-S cannot infect C57BL/6J or
B6-IFNAR1 KO mice, but infects neonatal B6.Cg-Tg (K18ACE2)2Prlmn/J demonstrating that the interaction with hACE2 is
required for infection, and 4) pre-treatment with antibodies that
speciﬁcally block the spike protein protected the mice from
infection (Figure 4). Lastly, previous studies showed that neonatal
C57BL/6J mice succumb to infection when challenged with the
parental VSV virus or with VSV virus where the glycoprotein (G)
was replaced by the Ebola Zaire glycoprotein, however C57BL/6J
mice do not succumb when challenged with VSV virus where G was
replaced by the Ebola Reston glycoprotein or with SARS-CoV-2
spike protein (18). This indicates that even in susceptible neonatal
mice, tissue tropism mediated by the envelope glycoprotein is
required for lethal infection. Interestingly, unlike SARS-CoV-2,
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can also be used to model tissue tropism and test therapeutics to
hypothetical variants of the spike without generating novel
infectious and potentially pathogenic variants of SARS-CoV-2 in
the lab.

markers including Il-1rn, Pdl1, Lilrb3 and Lilrb4 reﬂects a dynamic
host immune response and suggests that the models could be used to
assess combinations of anti-Spike and immunomodulatory products.
Although the absolute level of individual markers is different between
the models, there is striking similarity in the GO path analysis and the
individual genes upregulated in the brain in both models suggesting
that the rVSV-SARS2-S model can be used as effectively as the SARSCoV-2 model to test SARS-CoV-2 countermeasures targeting the
Spike protein.
Multiple studies have shown that antibodies targeting the
SARS-CoV-2’s spike-ACE2 interaction are critical for protection
however in vitro assays testing neutralization do not capture the
dynamics of viral replication mediated by tissue tropism,
pharmacokinetics and pharmacodynamics of therapeutics and
most importantly the complexity of host-pathogen interactions.
Animal models that require BSL3 containment are useful, but
severely increase the cost and complexity of studies, and few
facilities are set up for long-term or complex studies that can
accelerate testing of therapeutic targets. While the proposed rVSVSARS2-S model allows for easier testing, there are obvious
limitations including i) the viral replication is mediated by the
VSV machinery resulting in limited utility when testing
tharapeutics that do not target the spike -ACE2 interaction, ii)
while immunologically replete, the immune system in neonatal
mice is immature, so studies assessing host-pathogen interactions or
evaluating immunomodulatory agents should be interpreted
cautiously, and iii) the expression of human ACE2 under the K18
promotor is likely to result in altered tissue tropism. However the
model presents several advantages including speciﬁc entry and
spread mediated by the SARS-CoV-2 spike protein providing a
useful tool to test preventive and therapeutic strategies targeting the
spike protein in vivo under BSL-2 conditions. This model can be
used to test SARS-CoV-2 countermeasures that speciﬁcally target
the spike protein, investigate the role of spike protein in mediating
infection and/or antibody dependent enhancement (ADE) of
disease. Indeed, the studies comparing the efﬁcacy of different
antibody preparations in blocking infection by SARS-CoV-2 and
rVSV-SARS2-S illustrate the comparable utility of this VSV-based
animal model. Importantly, since the host’s immune response is
intact, strategies such as boosting host immune response and
combination therapies that target host immune response, SARSCoV-2 spike protein and RNA dependent RNA polymerase (RdRp)
as well as the contribution of Fc mediated effector function to viral
clearance can be tested in this model. Lastly, as the pandemic
continues to evolve, we are facing the emergence of new variants of
concern where changes to the spike protein are modifying the
afﬁnity to ACE2 and consequently the infectivity and disease
severity (39). Modeling the variants using the rVSV-SARS2-S
models, showed that the mutations in the spike protein led to
accelerated disease progression demonstrating the critical role of
SARS-CoV-2 spike glycoprotein on disease phenotype. Indeed, the
plasticity of the rVSV-SARS2-S model allows not only for rapid
development of animal models to address emerging variants but
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